Genitourinary Cancer

Tanya Dorff, MD, explains the developments of chemotherapy in firstline treatment for hormone-sensitive metastatic prostate cancer as well as personalized treatment in this population.

Dr. Clayton Lau, a prostate cancer expert, discusses the options for patients with early-stage prostate cancer and the importance of staying educated on this disease.

A recent study found an increased risk of dementia for patients with prostate cancer being treated with ADT, and those patients with the highest risk had been treated with ADT for the longest period of time.

Celestia Higao, MD, talks about the difficulty of discussing sexual health, particularly with male patients.

Deborah Watkins Bruner, RN, PhD, FAAN, discusses the results of a trial comparing quality of life after conventional radiotherapy and after a hypofractionated schedule for men at low-risk for prostate cancer.

Use of PSA tests between 2010 and 2012 at University of Texas Southwestern Medical Center did not significantly change despite the 2012 USPSTF recommendation against PSA screenings.

When treating patients with prostate cancer in survivorship care, Dan Spratt underscores the importance of being aware of potential mental health issues.

For men with positive needle biopsy for prostate cancer, active surveillance (AS) did not negatively impact their quality-of-life compared with men who had a negative prostate needle biopsy.

Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.

Immunotherapy is changing the cancer treatment game as therapies continue to be approved for more and more tumor types. This creates more responsibilities for oncology nurses.

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

Despite obesity as a risk factor for clear cell RCC, a high BMI is a prognostic factor for improved survival in patients with metastatic RCC.

Patients undergoing Androgen-deprivation therapy (ADT) for prostate cancer may be at risk of significant psychological effects.

Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treating different subsets of bladder cancer.

While urinary incontinence and erectile dysfunction are two burdensome side effects from prostate cancer treatment, new online programs are showing promise in helping men cope in both the short and long term.

The health benefits of yoga are many, but in the oncology setting, studies of the approach have focused primarily on women with breast cancer. However, a small, first-of-its-kind study by researchers at the Perelman School of Medicine at the University of Pennsylvania is exploring how yoga may also improve treatment-related symptoms in men who are undergoing radiotherapy for their prostate cancer. And the results, thus far, are promising.

To help patients decide whether active surveillance or a more aggressive approach is best to treat their localized, low-risk prostate cancer, researchers at Thomas Jefferson University created an online decision-support tool that relies on a trained nurse educator to help patients better understand their treatment options.

Celestia S. Higano, MD, of the Seattle Cancer Care Alliance, discusses sexual health services that are available to survivors of prostate cancer.

Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.

Alyson Moadel, PhD, director of psychosocial oncology, Albert Einstein College of Medicine, Montefiore Medical Center, discusses partner-related side effects of prostate cancer.

Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treatment for lymph node-positive bladder cancer.

Researchers have discovered that shorter, more intensive radiation treatment for patients in the early stages of prostate cancer can be performed without compromising cancer control.

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma.

Although androgen deprivation therapy (ADT) has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether ADT causes clinically significant depression.

The US Congress passed the Agent Orange Act of 1991 to address whether exposure to herbicides, such as Agent Orange, contributed to long-term health effects in Vietnam veterans.

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Sumanta K. Pal, MD, City of Hope Cancer Center, discusses the great strides in kidney cancer care that have been made in the past decade.

E. David Crawford, MD, professor of radiation oncology University of Colorado Denver, discusses the potential side effects of frequently used prostate cancer treatments.